排序方式: 共有92条查询结果,搜索用时 406 毫秒
61.
新生隐球菌荚膜基因CAP60对菌体荚膜形成的影响 总被引:2,自引:1,他引:1
目的:研究新生隐球菌荚膜相关基因CAP60对菌体荚膜形成的影响。方法:用PCR方法分离CAP60基因并测序鉴定,将该基因导入转化载体并转化cap60ura^-菌株,乳胶凝集试剂盒筛选转化分子。结果:部分转化子恢复莱膜的表型,表明得到的片段具有荚膜基因功能。结论:荚膜基因对新生隐球菌的荚膜形成都是必须的,缺失其中的任何一个基因都会使新生隐球菌变成无荚膜表型。 相似文献
62.
分子生物学技术在新生隐球菌分类鉴定和诊断… 总被引:1,自引:0,他引:1
近年来,分子生物学技术用于新生隐球菌的分类鉴定和诊断研究已取得很大进展,如染色体脉冲电泳分型,核酸探针技术,DNA指纹技术和酶链反应技术等分子鉴定和诊断方法比传统方法更具有特异,敏感和快速等优点。本文就这方面的有关研究情况作一综述。 相似文献
63.
聚合酶链反应检测病原真菌及新生隐球菌的实验研究 总被引:2,自引:0,他引:2
目的使临床系统性真菌病的诊断提高到分子水平。方法首先应用一对外侧的基于rDNA的真菌通用引物进行PCR扩增,此后应用新生隐球菌种特异性内侧引物对首轮扩增产物进行第二轮扩增鉴定。结果应用外侧引物对能对代表8属17种的25株医学重要真菌进行扩增,而对所有细菌和人DNA均为扩增阴性,内侧引物对仅对新生隐球菌获得扩增。应用两轮PCR扩增(通用PCR和随后的种特异性PCR)方法从获得临床标本到鉴定病原菌仅需8小时。结论这种依据PCR的检测和鉴定系统为临床快速诊断系统性真菌病提供了一种全新的实验方法并可望应用于临床 相似文献
64.
65.
特比萘芬软膏与疗霉舒软膏随机对照治疗浅部真菌病多中心临床研究 总被引:4,自引:0,他引:4
目的 比较研究山东齐鲁制药厂生产的1 % 特比萘芬软膏和诺华公司生产的1 % 疗霉舒软膏治疗浅部真菌病的有效性和安全性。方法 随机、多中心临床研究。两种药物的用药剂量和疗程相同,外涂患处,每日2 次,体股癣、花斑癣疗程1 周,手足癣和皮肤念珠菌病疗程2 周。结果 1 % 特比萘芬软膏治疗浅部真菌病,临床治愈率为70 .8 % ,总有效率96 .2 % ,真菌清除率为90 .6 % ,不良反应发生率0 .9 % ;对照组疗霉舒临床治愈率为74 .5 % ,总有效率97 .1 % ,真菌清除率为93 .1 % ,不良反应发生率为2 .0 % 。两种药物治疗浅部真菌病的临床疗效和安全性在统计学上差异均无显著性意义。结论1 % 特比萘芬软膏治疗浅部真菌病疗效好、安全性高,与1 % 疗霉舒软膏比较疗效相似。 相似文献
66.
目的 比较研究山东齐鲁制药厂生产的1%特比萘芬软膏和诺华公司生产的1%疗霉舒软膏治疗浅部真菌病的有效性和安全性。方法 随机、多中心临床研究。两种药物的用药剂量和疗程相同,外涂患外,每日2次,体股癣、花斑癣疗程1周,手足癣和皮肤念珠菌病疗程2周。结果 1%特比萘芬软膏治疗浅部真菌病,临床治愈率为70.8%,总有效率96.2%,真菌清除率为90.6%,不良反应发生率0.9%;对照组疗霉舒临床治愈率为7 相似文献
67.
68.
Objective To observe the clinical efficacy and safety of gahapentin in the treatment of postherpetic neuralgia. Methods A multicenter, randomized, double-blind, placebo-controlled, parallel design, 6-week study was performed. Patients with postherpetic neuralgia were recruited into this study and randomly divided into two groups to receive gabapentin or placebo 1800 mg daily in three divided doses with a forced titration schedule, respectively. The primary efficacy measure was change in the pain score based on a visual analogue scale from baseline to the final week of therapy, and secondary measure was the improvement in sleep quality scored on a 5-point severity scale. Efficacy and safety evaluation was performed at baseline, and 1, 3, and 6 weeks atter the treatment. Results One hundred and forty-one patients were recruited in four clinical centers, and 125 patients completed the trial, of whom 66 were in the treatment group and 59 in the control group. An improvement was observed in both pain scores and sleep scores on week 1, 3 and 6 in both two groups, and the improvement was greater in gabapentin-treated group than that in the control group. The response rate was 29.58% and 57.75%, respectively in gabapentin-treated group on week 1 and 3, com-pared to 13.04% and 40.58%, respectively, in the control group (t = 5.94, 4.12, respectively, both P <0.05).Gabapentin was well tolerated, and the most common adverse events were dizziness, vertigo, somnolence and transient abnormality of hepatic function. Conclusion Gabapentin could markedly reduce pain intensity and improve sleep quality with a low incidence of adverse events in patients with postherpetic neuralgia. 相似文献
69.
70.